Find Filgrastim manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

32RELATED EXCIPIENT COMPANIES

59EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API REF. PRICE (USD/KG)

GLOBAL SALES INFORMATION

US Medicaid

NA

API/FDF Prices: Book a Demo to
explore the features and consider
upgrading later

MARKET PLACE

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set

API Reference Price

read-more
read-more
[{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q2","strtotime":1652034600,"product":"PEGFILGRASTIM (PEGILATED FILGRASTIM),CON","address":"CAMUS HOUSE, 29-B, SURAJ NAGAR EAST, CIVIL LINES,","city":"JAIPUR, RAJASTHAN.","supplier":"CAMUS PHARMA PRIVATE LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW","customer":"PSK PHARMA LTD","customerCountry":"RUSSIA","quantity":"0.03","actualQuantity":"31.925","unit":"GMS","unitRateFc":"11020","totalValueFC":"342987","currency":"USD","unitRateINR":830321.06499608455,"date":"09-May-2022","totalValueINR":"26508000","totalValueInUsd":"342987","indian_port":"BOMBAY AIR","hs_no":"29379090","bill_no":"1270630","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"CAMUS HOUSE, 29-B, SURAJ NAGAR EAST, CIVIL LINES,, JAIPUR, RAJASTHAN.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663698600,"product":"FILGRASTIM IP(FILGRASTIM CONCENTRATED SO","address":"T-184 MIDC BHOSARI Contact No: 919373314247","city":"PUNE","supplier":"GENNOVA BIOPHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"AL BARAKA BANK PAKISTAN LTD","customerCountry":"PAKISTAN","quantity":"0.00","actualQuantity":"3.479","unit":"GMS","unitRateFc":"2991.7","totalValueFC":"10219.5","currency":"USD","unitRateINR":235412.47484909455,"date":"21-Sep-2022","totalValueINR":"819000","totalValueInUsd":"10219.5","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4318950","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"T-184 MIDC BHOSARI Contact No: 919373314247, PUNE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2022","qtr":"Q3","strtotime":1663698600,"product":"FILGRASTIM IP(FILGRASTIM CONCENTRATED SO","address":"T-184 MIDC BHOSARI Contact No: 919373314247","city":"PUNE","supplier":"GENNOVA BIOPHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"AL BARAKA BANK PAKISTAN LTD","customerCountry":"PAKISTAN","quantity":"0.01","actualQuantity":"5.047","unit":"GMS","unitRateFc":"2991.7","totalValueFC":"14823.9","currency":"USD","unitRateINR":235387.35882702598,"date":"21-Sep-2022","totalValueINR":"1188000","totalValueInUsd":"14823.9","indian_port":"BOMBAY AIR","hs_no":"29349990","bill_no":"4318950","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"BOMBAY AIR","supplierAddress":"T-184 MIDC BHOSARI Contact No: 919373314247, PUNE","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1693506600,"product":"PHARMACEUTICAL BULK CONCENTRATE FILGRASTIM IP (FILGRASTIM CONCENTRATED SOLUTIONIP) B.NO.:GCFB 2316 ,MFG. DT: AUG\/2023 E","address":"T-184 MIDC BHOSARI","city":"PUNE\/M.S.","supplier":"GENNOVA BIOPHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"UNDISCLOSED","customerCountry":"PAKISTAN","quantity":"0.01","actualQuantity":"0.005","unit":"KGS","unitRateFc":"2833330","totalValueFC":"14022.7","currency":"USD","unitRateINR":232800000,"date":"01-Sep-2023","totalValueINR":"1164000","totalValueInUsd":"14022.7","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"3638093","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"T-184 MIDC BHOSARI, PUNE\/M.S.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2023","qtr":"Q3","strtotime":1694457000,"product":"PEG FILGRASTIM (G-CSF) CONC. SOLUTION","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD","customerCountry":"RUSSIA","quantity":"0.03","actualQuantity":"34.009","unit":"GMS","unitRateFc":"1077960","totalValueFC":"441643","currency":"INR","unitRateINR":1077949.954423829,"date":"12-Sep-2023","totalValueINR":"36660000","totalValueInUsd":"441643","indian_port":"Ahmedabad Air","hs_no":"29379090","bill_no":"3877985","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1711909800,"product":"PEG FILGRASTIM (G-CSF) CONC. SOLUTION (PEG FILGRASTIM (G-CSF) CONC. SOLUTION)","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"MOSCOW DOMODEDOVO","customer":"PSK PHARMA LTD","customerCountry":"RUSSIA","quantity":"0.03","actualQuantity":"34.521","unit":"GMS","unitRateFc":"1078350","totalValueFC":"445778","currency":"INR","unitRateINR":1078350,"date":"01-Apr-2024","totalValueINR":"37225720.35","totalValueInUsd":"445778","indian_port":"Ahmedabad Air","hs_no":"29379090","bill_no":"8809807","productDescription":"API","marketType":"","country":"RUSSIA","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q2","strtotime":1715797800,"product":"PHARMACEUTICAL BULK CONCENTRATE FILGRASTIM IP (FILGRASTIM CONCENTRATED SOLUTIONIP) BATCH NO.:GCFB2414 MFG.DT: APR\/2024","address":"T-184 MIDC BHOSARI","city":"PUNE\/M.S.","supplier":"GENNOVA BIOPHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"UNDISCLOSED","customerCountry":"PAKISTAN","quantity":"0.01","actualQuantity":"0.005","unit":"KGS","unitRateFc":"2825402","totalValueFC":"13867.4","currency":"USD","unitRateINR":231181679.99999997,"date":"16-May-2024","totalValueINR":"1155908.4","totalValueInUsd":"13867.4","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"9928346","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"T-184 MIDC BHOSARI, PUNE\/M.S.","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2024","qtr":"Q4","strtotime":1727721000,"product":"PEG FILGRASTIM (G-CSF) CONC. SOLUTION (PEG FILGRASTIM (G-CSF) CONC. SOLUTION)","address":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H","city":"AHMEDABAD,GUJARAT","supplier":"ZYDUS LIFESCIENCES LTD","supplierCountry":"INDIA","foreign_port":"LAHORE","customer":"BF BIOSCIENCES LTD","customerCountry":"PAKISTAN","quantity":"0.03","actualQuantity":"33.259","unit":"GMS","unitRateFc":"4150","totalValueFC":"136031.5","currency":"USD","unitRateINR":343674.2024715115,"date":"01-Oct-2024","totalValueINR":"11430260.3","totalValueInUsd":"136031.5","indian_port":"Ahmedabad Air","hs_no":"29379090","bill_no":"4505105","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Ahmedabad Air","supplierAddress":"ZYDUS TOWER, SARKHEJ-GANDHINAGAR,H, AHMEDABAD,GUJARAT","customerAddress":""},{"dataSource":"API Export","activeIngredients":"","year":"2025","qtr":"Q1","strtotime":1739817000,"product":"PHARMACEUTICAL BULK CONCENTRATE FILGRASTIM IP (FILGRASTIM CONCENTRATED SOLUTION)B.NO.:GCFB 2502,MFG. DT: JAN\/2025 EXPIR","address":"T-184 MIDC BHOSARI","city":"PUNE\/M.S.","supplier":"GENNOVA BIOPHARMACEUTICALS LTD","supplierCountry":"INDIA","foreign_port":"KARACHI -","customer":"UNDISCLOSED","customerCountry":"PAKISTAN","quantity":"0.01","actualQuantity":"0.012","unit":"KGS","unitRateFc":"2866666.7","totalValueFC":"33787.1","currency":"USD","unitRateINR":244855250,"date":"18-Feb-2025","totalValueINR":"2938263","totalValueInUsd":"33787.1","indian_port":"Bombay Air","hs_no":"29349990","bill_no":"8259702","productDescription":"API","marketType":"","country":"PAKISTAN","selfForZScoreResived":"Pharma Grade","supplierPort":"Bombay Air","supplierAddress":"T-184 MIDC BHOSARI, PUNE\/M.S.","customerAddress":""}]
09-May-2022
18-Feb-2025
KGS
overview
Loading...

Average Price (USD/KGS)

Number of Transactions

Total Quantity (KGS)

Total Value (USD)

Quantity (KGS) & Unit rate (USD/KGS) over time

API/FDF Prices: Book a Demo to explore the features and consider upgrading later

API Imports and Exports

Importing Country Total Quantity
(KGS)
Average Price
(USD/KGS)
Number of Transactions

Upgrade, download data, analyse, strategize, subscribe with us contact

Drugs in Development

read-more
read-more

Details:

The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).


Lead Product(s): Natural Killer Cell,Filgrastim,Fludarabine Phosphate

Therapeutic Area: Oncology Brand Name: KDS-1001

Study Phase: Phase IProduct Type: Cell and Gene therapy

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 03, 2020

Sanofi Company Banner

01

Sanofi

France
arrow

Lead Product(s) : Natural Killer Cell,Filgrastim,Fludarabine Phosphate

Therapeutic Area : Oncology

Highest Development Status : Phase I

Partner/Sponsor/Collaborator : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : The abstract showcases the potential of the Company’s NK cell therapy to treat relapsed/refractory acute myeloid leukemia (R/R AML).

Product Name : KDS-1001

Product Type : Cell and Gene therapy

Upfront Cash : Inapplicable

October 03, 2020

Sanofi Company Banner

Details:

Zefylti (filgrastim biosimilar) is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by recombinant DNA technology. It is indicated for the treatment of febrile neutropenia.


Lead Product(s): Filgrastim

Therapeutic Area: Hematology Brand Name: Zefylti

Study Phase: Approved FDFProduct Type: Protein

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 13, 2025

blank

02

Specialty & Agro Chemical
Not Confirmed
Specialty & Agro Chemical
Not Confirmed

Details : Zefylti (filgrastim biosimilar) is a human granulocyte colony-stimulating factor (G-CSF)‚ produced by recombinant DNA technology. It is indicated for the treatment of febrile neutropenia.

Product Name : Zefylti

Product Type : Protein

Upfront Cash : Inapplicable

May 13, 2025

blank

Details:

BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia.


Lead Product(s): Motixafortide,Filgrastim

Therapeutic Area: Oncology Brand Name: Aphexda

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Ayrmid

Deal Size: $97.0 million Upfront Cash: $10.0 million

Deal Type: Licensing Agreement November 21, 2024

blank

03

BioLineRx

Israel
arrow
Specialty & Agro Chemical
Not Confirmed

BioLineRx

Israel
arrow
Specialty & Agro Chemical
Not Confirmed

Details : BioLineRx granted Ayrmid an exclusive license to develop and commercialize Aphexda (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia.

Product Name : Aphexda

Product Type : Peptide

Upfront Cash : $10.0 million

November 21, 2024

blank

Details:

The net proceeds will be used to advance the commercialization of APHEXDA (motixafortide) approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.


Lead Product(s): Motixafortide,Filgrastim

Therapeutic Area: Oncology Brand Name: Aphexda

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Blackrock

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Financing October 04, 2024

blank

04

BioLineRx

Israel
arrow
Specialty & Agro Chemical
Not Confirmed

BioLineRx

Israel
arrow
Specialty & Agro Chemical
Not Confirmed

Details : The net proceeds will be used to advance the commercialization of APHEXDA (motixafortide) approved in the U.S. for stem cell mobilization for autologous transplantation in multiple myeloma.

Product Name : Aphexda

Product Type : Peptide

Upfront Cash : Undisclosed

October 04, 2024

blank

Details:

BioLineRx plans to use proceeds for the commercialization of APHEXDA (motixafortide) in the U.S. for stem cell mobilization in multiple myeloma patients.


Lead Product(s): Motixafortide,Filgrastim

Therapeutic Area: Oncology Brand Name: Aphexda

Study Phase: Approved FDFProduct Type: Peptide

Sponsor: Jonestrading Institutional Services

Deal Size: $6.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering January 04, 2024

blank

05

BioLineRx

Israel
arrow
Specialty & Agro Chemical
Not Confirmed

BioLineRx

Israel
arrow
Specialty & Agro Chemical
Not Confirmed

Lead Product(s) : Motixafortide,Filgrastim

Therapeutic Area : Oncology

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Jonestrading Institutional Services

Deal Size : $6.0 million

Deal Type : Public Offering

Details : BioLineRx plans to use proceeds for the commercialization of APHEXDA (motixafortide) in the U.S. for stem cell mobilization in multiple myeloma patients.

Product Name : Aphexda

Product Type : Peptide

Upfront Cash : Undisclosed

January 04, 2024

blank

Details:

RELEUKO® (filgrastim-ayow) is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. RELEUKO® in the U.S. is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients with nonmyeloid malignancies.


Lead Product(s): Filgrastim

Therapeutic Area: Hematology Brand Name: Releuko

Study Phase: Approved FDFProduct Type: Protein

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 22, 2022

blank

06

Specialty & Agro Chemical
Not Confirmed
Specialty & Agro Chemical
Not Confirmed

Details : RELEUKO® (filgrastim-ayow) is used to treat neutropenia which is commonly experienced by patients undergoing chemotherapy. RELEUKO® in the U.S. is indicated to decrease the incidence of infection‚ as manifested by febrile neutropenia‚ in patients w...

Product Name : Releuko

Product Type : Protein

Upfront Cash : Inapplicable

November 22, 2022

blank

Details:

U.S. FDA approved biologics license application for RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen, to treat neutropenia which is commonly experienced by patients undergoing chemotherapy, acute myeloid leukemia and nonmyeloid malignancies.


Lead Product(s): Filgrastim

Therapeutic Area: Hematology Brand Name: Releuko

Study Phase: Approved FDFProduct Type: Protein

Sponsor: Kashiv BioSciences

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 03, 2022

blank

07

Specialty & Agro Chemical
Not Confirmed
Specialty & Agro Chemical
Not Confirmed

Details : U.S. FDA approved biologics license application for RELEUKO (filgrastim-ayow), a biosimilar referencing Neupogen, to treat neutropenia which is commonly experienced by patients undergoing chemotherapy, acute myeloid leukemia and nonmyeloid malignancies.

Product Name : Releuko

Product Type : Protein

Upfront Cash : Inapplicable

January 03, 2022

blank

Details:

The study was designed to evaluate the safety and efficacy of Recardio's lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with stent placement.


Lead Product(s): Dutogliptin Tartrate,Filgrastim

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 19, 2021

blank

08

Recardio

U.S.A
arrow
Specialty & Agro Chemical
Not Confirmed

Recardio

U.S.A
arrow
Specialty & Agro Chemical
Not Confirmed

Details : The study was designed to evaluate the safety and efficacy of Recardio's lead candidate dutogliptin to restore lost myocardial function in patients who experience STEMI, a severe form of heart attack, and receive percutaneous coronary intervention with s...

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

May 19, 2021

blank

Details:

Amneal Pharmaceuticals has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and novel 505(b)(2) drugs.


Lead Product(s): Filgrastim

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Protein

Sponsor: Amneal Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition May 04, 2021

blank

09

Specialty & Agro Chemical
Not Confirmed
Specialty & Agro Chemical
Not Confirmed

Details : Amneal Pharmaceuticals has completed its previously announced acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv focused on the development of complex generics, innovative drug delivery platforms and no...

Product Name : Undisclosed

Product Type : Protein

Upfront Cash : Undisclosed

May 04, 2021

blank

Details:

In addition, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction & CHF, with the potential of improving heart function, quality of life & survival.


Lead Product(s): Dutogliptin Tartrate,Filgrastim

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Other Small Molecule

Sponsor: Inapplicable

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 17, 2020

blank

10

Recardio

U.S.A
arrow
Specialty & Agro Chemical
Not Confirmed

Recardio

U.S.A
arrow
Specialty & Agro Chemical
Not Confirmed

Details : In addition, Recardio will fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction & CHF, with the potential of improving heart function, quality of life ...

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

December 17, 2020

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Film Formers & Plasticizers

read-more
read-more

Solubilizers

read-more
read-more

Parenteral

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Taste Masking

read-more
read-more

Coating Systems & Additives

read-more
read-more

Topical

read-more
read-more

Emulsifying Agents

read-more
read-more

Direct Compression

read-more
read-more

Co-Processed Excipients

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Soft Gelatin

read-more
read-more

Rheology Modifiers

read-more
read-more

API Stability Enhancers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty